Phase 2 N=234 Study Of 323U66 SR In Major Depressive Disorder
Depressive Disorder
Primary: Change From Baseline in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at Week 8 in Observed Cases — -16.8 Score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=16 Gemfibrozil for Nicotine Smoking Cessation
Smoking Cessation
Primary: Exhaled Carbon Monoxide (CO) — 10.88; 21.63 Parts p/million
Phase 2 N=38 Dasatinib in Relapsed or Refractory Non-Hodgkin's Lymphoma
Non-Hodgkin's Lymphoma
Primary: Maximum Tolerated Dose — 200 milligrams PO daily
Phase 2 N=2 Orlistat for the Treatment of Type I Hyperlipoproteinemia
Hyperlipoproteinemia Type I · Hypertriglyceridemia
Primary: Fasting Serum Triglycerides — 705; 1827; 1511; 1007 mg/dL
Phase 3 N=384 A 12-month, Randomized, Efficacy and Safety Study of 0.5 mg Ranibizumab vs Laser in Chinese Diabetic Macular Edema (DME) Patients
Diabetic Macular Edema · Visual Impairment
Primary: Mean Average Change From Baseline in Best-Corrected Visual Acuity (BCVA) (Letters) to Month 1 Through 12 — 6.8; 1.1 letters — p=<0.001
Phase 4 N=302 A Study to Evaluate Persistence of Hepatitis B Antibodies, Immunogenicity and Safety of Engerix™-B Kinder Challenge Dose, in Adolescents Vaccinated With Four Doses of Infanrix™ Hexa During Infancy
Hepatitis B
Primary: Anti-Hepatitis B Surface (Anti-HBs) Antibody Concentrations — 1975.7 mIU/mL
Phase 1 N=13 Pharmacokinetics and Preliminary Bioequivalence of Triferic (Ferric Pyrophosphate Citrate) Administered Via Hemodialysate and Intravenously to Adult CKD-5HD Patients
End Stage Renal Disease
Primary: Pharmacokinetics (PK) of Triferic Iron Administered Via Hemodialysate in Adult CKD-5HD Patients: Cmax. — 124; 131; 124 microgram per deciliter
Phase 4 N=20 Diurnal Variation of Plasminogen Activator Inhibitor-1
Metabolic Syndrome X
Primary: Plasminogen Activator Inhibitor-1 (PAI-1) Levels — 41.5; 42.9 ng/ml
Phase 1 N=12 Pharmacokinetics of Triferic (Ferric Pyrophosphate Citrate) Administered Intravenously to Healthy Adult Volunteers
End Stage Renal Disease
Primary: Pharmacokinetics of Triferic Iron Administered IV to Healthy Adults: Maximum Drug Concentration (Cmax) of Total Serum Iron — 102; 44.1 microgram/deciliter
Phase 2 N=20 Study of Lenvatinib (E7080) in Participants With Advanced Hepatocellular Carcinoma (HCC)
Hepatocellular Carcinoma
Primary: Phase 1: Maximum Tolerated Dose (MTD) of Lenvatinib — 12; 8 milligram (mg)
Phase 2 N=99 Efficacy, Safety and Pharmacokinetics of Sugammadex (Org 25969; MK-8616) at 3 Different Time Points After 0.6 mg/kg Esmeron® in Male Participants (P05940; MK-8616-020).
Neuromuscular Blockade
Primary: Mean Time From Start of Study Treatment Administration to Recovery of the T4/T1 Ratio to 0.9 — 52.05; 22.73; 4.93; 6.25 minutes
Phase 2 N=60 Pazopanib and Paclitaxel as First-Line Treatment for Subjects With Unresectable Stage III and Stage IV Melanoma
Stage III Melanoma · Stage IV Melanoma · Unresectable Melanoma
Primary: Percentage of Participants With Progression-free Survival at 6 Months — 68 percentage of participants
N/A N=601 Post-Authorization Long-term Safety Surveillance on Antihypertensive Treatment With Kanarb® (Fimasartan)
Essential Hypertension
Primary: Number of Participants Experiencing AEs or ADRs — 184; 59 Participants
Phase 4 N=14 A Study of Continuous Subcutaneous Insulin Infusion (CSII) Pump Function in Subjects With Type 1 Diabetes With Recombinant Human Hyaluronidase (rHuPH20)
Type 1 Diabetes Mellitus
Primary: Part 1: Area Under the Curve (AUC) of Glucose Infusion Rate (GIR) From 0-6 Hours
Phase 3 N=122 GW815SF For Chronic Obstructive Pulmonary Disease (Chronic Bronchitis, Emphysema)
Pulmonary Disease, Chronic Obstructive
Primary: Number of Participants With Any Adverse Events (AEs) and Serious AEs (SAEs) — 120; 27 Participants